Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide: from tragedy to promise.

Roger von Moos1, Rahel Stolz, Thomas Cerny

  • 1Department of Internal Medicine (Oncology), Kantonsspital, CH-9007 St. Gallen, Switzerland. roger.vonmoos@kssg.ch

Swiss Medical Weekly
|March 20, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Prostate cancer and prostatic diseases·2026
Same author

The Diagnostic Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Patients with Rising PSA After Radical Prostatectomy and Postoperative Radiotherapy: A Systematic Review and Meta-analysis.

European urology oncology·2026
Same author

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.

The Lancet. Oncology·2026
Same author

Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium.

The Lancet. Oncology·2026
Same author

Hot flushes during ADT for prostate cancer - a clinical rationale for a neurokinin 3 receptor antagonist.

Nature reviews. Urology·2026

Thalidomide, an immunomodulatory and antiangiogenic drug, shows activity across various diseases. Ongoing trials explore its optimal dosage and combination therapies for enhanced therapeutic benefits.

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Thalidomide is a drug with immunomodulatory and antiangiogenic properties.
  • Its precise mechanism of action remains under investigation.
  • It has demonstrated efficacy in treating a range of diseases.

Observation:

  • Clinical trials are actively evaluating thalidomide's optimal dosage.
  • Research is focused on the benefits of combining thalidomide with other therapeutic agents.
  • This review synthesizes key clinical trial data for thalidomide.

Findings:

  • Thalidomide exhibits multifaceted biological activities.
  • Evidence suggests its potential in diverse pathological conditions.
  • Clinical studies are refining its application and combination strategies.

Related Experiment Videos

Implications:

  • Further research into thalidomide's mechanism could unlock new therapeutic avenues.
  • Optimizing thalidomide dosage and combinations may improve patient outcomes.
  • This review provides a valuable resource for understanding thalidomide's clinical applications.